Abstract
Objective: To examine the effectiveness of first-trimester fetal trisomy 21 screening using a combination of maternal age, nuchal translucency thickness (NT) and maternal serum free beta-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A) levels in a predominantly Chinese population in Hong Kong. Methods: This was a prospective study over a 1.5-year period of 2990 women who underwent combined screening for trisomy 21 between 11 + 0 and 13 + 6 weeks of gestation in a university fetal medicine unit. NT was measured according to the criteria set by The Fetal Medicine Foundation (FMF), maternal serum free β-hCG and PAPP-A levels were measured, and the risk of trisomy 21 was calculated using The FMF's algorithm. Fetal karyotyping was advised when the risk was 1:300 or above. All subjects were followed up for pregnancy and fetal outcome. Results: Of the 2990 women who underwent the screening program, 99% were Chinese. There were 57 twin pregnancies, giving a total of 3047 fetuses. Thirty-one percent of the women were 35 years old or above. One hundred and eighty-five (6.1%) fetuses were screen-positive; this included 14 cases of trisomy 21 and 17 cases of other chromosomal abnormalities. The positive predictive value was 16.7%. Among the 2862 screen-negative fetuses, only 18 (0.6%) cases had an unknown fetal outcome. There were no cases in which trisomy 21 was missed and the infant was liveborn. Conclusion: First-trimester combined screening for fetal trisomy 21 is highly effective among Chinese subjects. Copyright © 2006 ISUOG. Published by John Wiley & Sons, Ltd.
Author supplied keywords
Cite
CITATION STYLE
Leung, T. Y., Chan, L. W., Leung, T. N., Fung, T. Y., Sahota, D. S., Spencer, K., & Lau, T. K. (2007). First-trimester combined screening for trisomy 21 in a predominantly Chinese population. Ultrasound in Obstetrics and Gynecology, 29(1), 14–17. https://doi.org/10.1002/uog.3893
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.